NCT01044485View on ClinicalTrials.gov

Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

November 30, 2011

Conditions
Metastatic Breast Cancer
Interventions
DRUG

lapatinib

escalation dose from 1250 to 1500 mg in association with docetaxel

DRUG

docetaxel

escalation dose from 75 mg/m2 to 100 mg/m2 in association with lapatinib

Trial Locations (1)

21000

Centre Georges François Leclerc, Dijon

Sponsors

Collaborators (2)

GlaxoSmithKline
Sanofi
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Sanofi

INDUSTRY

lead

Centre Georges Francois Leclerc

OTHER